- 24 January 2023SV NewsBritain is losing its chance to become a life sciences superpower
- 16 January 2023SV NewsBritish Patient Capital and Mubadala Invest in SV Biotech Crossover Opportunities Fund
- 9 January 2023Portfolio NewsImbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
- 9 January 2023Portfolio NewsTRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases
- 9 January 2023Portfolio NewsExclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio
- 5 January 2023Portfolio NewsQurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
- 26 December 2022Portfolio NewsWhy a lucky few may help the rest of us beat disease
- 20 December 2022Portfolio NewsMestag Therapeutics appoints Prof. Ton Logtenberg as Chair
- 13 December 2022Portfolio NewsIn its largest single-asset purchase ever, Takeda snaps up TYK2 drug [from SV portfolio company] for $4B upfront
- 13 December 2022Portfolio NewsTakeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
- 13 December 2022Portfolio NewsDementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases
- 8 December 2022Portfolio NewsQurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS